Oxurion Announces Intent to Acquire International CRO

Leuven, Belgium-based pharmaceutical outsourcing firm, Oxurion NV, has signed a letter of intent to acquire a majority stake in a prominent international Clinical Research Organization (CRO). This strategic move aligns with Oxurion's plan to bolster its integrated clinical development model. The targeted CRO operates across Europe, North Africa, and the Middle East, executing comprehensive clinical trial lifecycle management and regulatory services. In 2025, the CRO generated €3 million in revenue, managing over 300 projects. It anticipates a 12% growth annually for the next three years, aside from group synergies. The acquisition, valuing the CRO at €3,712,500, will be funded with cash and Oxurion shares. Completion of due diligence and necessary agreements is expected by May 2026. The exclusivity period extends to June, allowing no rival bids.